Company intelligence / Profile preview
Confluence Pharmaceuticals
Carmel, Indiana, United Statesconfluencepharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Confluence Pharmaceuticals is currently conducting Phase II clinical trials for its lead compound acamprosate for the treatment of Fragile X Syndrome. A double-blind placebo-controlled study demonstrated improvements across several disorder-relevant domains including expressive language, social engagement, anxiety, and hyperactivity.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Indiana University School of MedicineCincinnati Children's Hospital Medical Center
Beyond the preview
Go deeper on Confluence Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Confluence Pharmaceuticals.